Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S1. Patient Characteristics.</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Qingsheng Xu (17078830) (author)
Outros Autores:	Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Publicado em:	2025
Assuntos:	Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados